ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 96.98 Billion KRW | 19.66% |
| 2022 | 81.05 Billion KRW | -22.77% |
| 2021 | 104.95 Billion KRW | 46.75% |
| 2020 | 71.51 Billion KRW | -0.81% |
| 2019 | 72.1 Billion KRW | -14.25% |
| 2018 | 84.08 Billion KRW | -55.75% |
| 2017 | 190.03 Billion KRW | 10.08% |
| 2016 | 172.62 Billion KRW | -1.72% |
| 2015 | 175.64 Billion KRW | 18.07% |
| 2014 | 148.76 Billion KRW | 6.54% |
| 2013 | 139.63 Billion KRW | 2.49% |
| 2012 | 136.24 Billion KRW | 10.28% |
| 2011 | 123.54 Billion KRW | 45.58% |
| 2010 | 84.86 Billion KRW | -18.65% |
| 2009 | 104.31 Billion KRW | 6.25% |
| 2008 | 98.17 Billion KRW | 18.69% |
| 2007 | 82.71 Billion KRW | 13.5% |
| 2006 | 72.88 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 91.31 Billion KRW | -5.85% |
| 2023 Q4 | 96.98 Billion KRW | 16.5% |
| 2023 FY | 96.98 Billion KRW | 19.66% |
| 2023 Q1 | 83.03 Billion KRW | 2.45% |
| 2023 Q2 | 82.32 Billion KRW | -0.86% |
| 2023 Q3 | 83.25 Billion KRW | 1.13% |
| 2022 Q4 | 81.05 Billion KRW | 0.08% |
| 2022 Q1 | 92.12 Billion KRW | 0.0% |
| 2022 Q3 | 80.98 Billion KRW | -15.64% |
| 2022 Q2 | 95.99 Billion KRW | 4.2% |
| 2022 FY | 81.05 Billion KRW | -22.77% |
| 2021 Q2 | 71.91 Billion KRW | -0.04% |
| 2021 FY | 104.95 Billion KRW | 46.75% |
| 2021 Q1 | 71.94 Billion KRW | 0.59% |
| 2021 Q3 | 82.12 Billion KRW | 14.2% |
| 2020 Q1 | 74.05 Billion KRW | 2.7% |
| 2020 Q4 | 71.51 Billion KRW | -11.97% |
| 2020 Q3 | 81.24 Billion KRW | -1.99% |
| 2020 Q2 | 82.89 Billion KRW | 11.94% |
| 2020 FY | 71.51 Billion KRW | -0.81% |
| 2019 Q3 | 71.77 Billion KRW | -4.78% |
| 2019 Q1 | 82.67 Billion KRW | -1.68% |
| 2019 Q2 | 75.38 Billion KRW | -8.82% |
| 2019 FY | 72.1 Billion KRW | -14.25% |
| 2019 Q4 | 72.1 Billion KRW | 0.45% |
| 2018 Q3 | 186.58 Billion KRW | -4.62% |
| 2018 FY | 84.08 Billion KRW | -55.75% |
| 2018 Q4 | 84.08 Billion KRW | -54.93% |
| 2018 Q2 | 195.63 Billion KRW | 10.71% |
| 2018 Q1 | 176.71 Billion KRW | -7.01% |
| 2017 FY | 190.03 Billion KRW | 10.08% |
| 2017 Q1 | 193.36 Billion KRW | 12.01% |
| 2017 Q4 | 190.03 Billion KRW | 2.7% |
| 2017 Q2 | 195.25 Billion KRW | 0.98% |
| 2017 Q3 | 185.04 Billion KRW | -5.23% |
| 2016 Q2 | 186.06 Billion KRW | -3.32% |
| 2016 Q1 | 192.46 Billion KRW | 9.58% |
| 2016 Q4 | 172.62 Billion KRW | -3.62% |
| 2016 Q3 | 179.1 Billion KRW | -3.74% |
| 2016 FY | 172.62 Billion KRW | -1.72% |
| 2015 FY | 175.64 Billion KRW | 18.07% |
| 2015 Q1 | 177.7 Billion KRW | 19.45% |
| 2015 Q4 | 175.64 Billion KRW | -2.2% |
| 2015 Q2 | 170.78 Billion KRW | -3.89% |
| 2015 Q3 | 179.59 Billion KRW | 5.16% |
| 2014 FY | 148.76 Billion KRW | 6.54% |
| 2014 Q4 | 148.76 Billion KRW | 1.58% |
| 2014 Q1 | 137.97 Billion KRW | -1.19% |
| 2014 Q2 | 143.04 Billion KRW | 3.68% |
| 2014 Q3 | 146.45 Billion KRW | 2.39% |
| 2013 Q2 | 146.5 Billion KRW | 7.34% |
| 2013 FY | 139.63 Billion KRW | 2.49% |
| 2013 Q4 | 139.63 Billion KRW | -3.36% |
| 2013 Q3 | 144.48 Billion KRW | -1.38% |
| 2013 Q1 | 136.49 Billion KRW | 0.18% |
| 2012 FY | 136.24 Billion KRW | 10.28% |
| 2012 Q4 | 136.24 Billion KRW | 0.0% |
| 2011 FY | 123.54 Billion KRW | 45.58% |
| 2011 Q3 | 55.32 Billion KRW | -1.3% |
| 2011 Q2 | 56.05 Billion KRW | -8.21% |
| 2011 Q1 | 61.07 Billion KRW | 0.0% |
| 2010 Q2 | 81.69 Billion KRW | -1.45% |
| 2010 Q3 | 68.95 Billion KRW | -15.6% |
| 2010 FY | 84.86 Billion KRW | -18.65% |
| 2010 Q1 | 82.89 Billion KRW | 0.0% |
| 2009 Q2 | 83.87 Billion KRW | -2.51% |
| 2009 FY | 104.31 Billion KRW | 6.25% |
| 2009 Q3 | 80.22 Billion KRW | -4.35% |
| 2009 Q1 | 86.03 Billion KRW | 0.0% |
| 2008 Q2 | 73.59 Billion KRW | -10.81% |
| 2008 FY | 98.17 Billion KRW | 18.69% |
| 2008 Q3 | 86.14 Billion KRW | 17.07% |
| 2008 Q1 | 82.5 Billion KRW | 0.0% |
| 2007 Q2 | 59.41 Billion KRW | -66.95% |
| 2007 Q1 | 179.76 Billion KRW | 0.0% |
| 2007 Q3 | 62 Billion KRW | 4.35% |
| 2007 FY | 82.71 Billion KRW | 13.5% |
| 2006 FY | 72.88 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Green Cross Holdings Corporation | 3737.7 Billion KRW | 97.405% |
| Green Cross Holdings Corporation | 2643.31 Billion KRW | 96.331% |
| Pharmicell Co., Ltd. | 99.19 Billion KRW | 2.221% |
| Green Cross Corporation | 2643.31 Billion KRW | 96.331% |
| GeneOne Life Science, Inc. | 151 Billion KRW | 35.773% |
| Celltrion, Inc. | 19917.53 Billion KRW | 99.513% |
| Samsung Biologics Co.,Ltd. | 16046.19 Billion KRW | 99.396% |
| SK bioscience Co.,Ltd. | 1852.43 Billion KRW | 94.764% |
| SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | 86.589% |
| Prestige BioPharma Limited | 711.72 Billion KRW | 86.373% |